title: Hyperuricemia and gout: an update.
abstract: Gout may be a primary or a secondary disorder. In both types of gout, overproduction or underexcretion of uric acid, or a combination of these abnormalities, may be the underlying mechanism. Controversy exists over the need for treatment of asymptomatic hyperuricemia. Treatment of tophi requires use of both uricosurics and allopurinol. A xanthine oxidase inhibitor is the drug of choice for patients with uric acid stones and for those with renal insufficiency.
mesh_terms: D000493:Allopurinol / Q000627:therapeutic use; D005260:Female; D006073:Gout / Q000178:diet therapy / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood* / Q000378:metabolism / Q000652:urine; D014528:Uricosuric Agents / Q000627:therapeutic use; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
chemical_list: D014528:Uricosuric Agents; D014527:Uric Acid; D000493:Allopurinol; D014969:Xanthine Oxidase